C difficile Awareness Month: Breakthroughs and Setbacks

November is C difficile Awareness Month. We're recapping the most significant potential therapies and remaining challenges from the past month.

November is C difficile Awareness Month. We're recapping the most significant potential therapies and remaining challenges from the past month.

November is Clostridioides difficile (C diff) Awareness Month.

“Usually for antibiotic awareness you have a week,” said Dr. Teena Chopra, “But for C diff a whole month has been dedicated, for a reason.”

Each year, this Gram-positive, highly infectious and resilient bacterium casuses an estimated half a millon infections and a billion dollars in healthcare-related costs in the US alone.

To raise awareness of the high prevalence and mortality of C diff, as well as the most promising therapies, we're recapping our most relevant C diff coverage from the past month.

C difficile, Antimicrobials, and the Patients Most Affected

In the latest episode of the Contagion Community podcast, Dr. Teena Chopra discusses the global need to do more to prevent healthcare-associated infections like C difficile in vulnerable patient populations.

New Therapeutic Offers Promise for Recurrent C Diff Infection

An easy-to-administer oral biologic kept repeat C difficile infections at bay in a new study.

CDI Biotherapeutic RBX2660 Outperforms Placebo in Phase 3 Trial

The closely watched therapeutic candidate led to long-term responses in 90% of patients who benefited from the therapy.

By Raising Awareness of C diff, Foundation Hopes to Minimize Risk

The Peggy Lillis Foundation hopes to use the month to increase the public’s awareness of the dangers of the C difficile infection.

FDA PDUFA Date Set for C diff Drug, SER-109

The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.